Viking Therapeutics, Inc. (NASDAQ:VKTX) has been assigned an average broker rating score of 1.00 (Strong Buy) from the three analysts that provide coverage for the stock, Zacks Investment Research reports. Three equities research analysts have rated the stock with a strong buy rating.

Brokerages have set a twelve-month consensus price objective of $7.13 for the company and are expecting that the company will post ($0.19) EPS for the current quarter, according to Zacks. Zacks has also assigned Viking Therapeutics an industry rank of 98 out of 265 based on the ratings given to its competitors.

A number of analysts recently issued reports on VKTX shares. Roth Capital set a $6.00 price target on shares of Viking Therapeutics and gave the stock a “buy” rating in a report on Wednesday. Maxim Group set a $8.00 price objective on shares of Viking Therapeutics and gave the company a “buy” rating in a report on Tuesday, November 28th. HC Wainwright reaffirmed a “buy” rating and set a $7.00 price objective on shares of Viking Therapeutics in a report on Friday, November 10th. Finally, ValuEngine downgraded shares of Viking Therapeutics from a “hold” rating to a “sell” rating in a report on Friday.

Shares of Viking Therapeutics (VKTX) traded down $0.02 during midday trading on Thursday, reaching $3.02. 732,375 shares of the company were exchanged, compared to its average volume of 502,873. Viking Therapeutics has a 12-month low of $0.88 and a 12-month high of $3.24.

Viking Therapeutics (NASDAQ:VKTX) last announced its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.19) by ($0.03). analysts anticipate that Viking Therapeutics will post -0.86 EPS for the current fiscal year.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Citadel Advisors LLC purchased a new position in Viking Therapeutics during the third quarter valued at $108,000. Renaissance Technologies LLC lifted its holdings in Viking Therapeutics by 62.9% during the first quarter. Renaissance Technologies LLC now owns 265,800 shares of the biotechnology company’s stock valued at $388,000 after purchasing an additional 102,600 shares in the last quarter. Virtu KCG Holdings LLC purchased a new position in Viking Therapeutics during the second quarter valued at $124,000. Sphera Funds Management LTD. purchased a new position in Viking Therapeutics during the third quarter valued at $554,000. Finally, Sabby Management LLC purchased a new position in Viking Therapeutics during the second quarter valued at $525,000. 7.50% of the stock is currently owned by institutional investors and hedge funds.

WARNING: This story was published by Watch List News and is owned by of Watch List News. If you are viewing this story on another site, it was illegally stolen and republished in violation of international copyright & trademark laws. The legal version of this story can be viewed at https://www.watchlistnews.com/zacks-viking-therapeutics-inc-vktx-given-average-rating-of-strong-buy-by-brokerages/1741969.html.

About Viking Therapeutics

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the development of therapies for metabolic and endocrine disorders. The Company’s clinical program, VK5211, is an orally available drug candidate, which is in Phase II clinical trial for acute rehabilitation following non-elective hip fracture surgery.

Get a free copy of the Zacks research report on Viking Therapeutics (VKTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Viking Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Viking Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.